FDA Peptides Meeting July 2026: What Happens After the PCAC Vote

On July 23–24, 2026, FDA’s Pharmacy Compounding Advisory Committee (PCAC) will review seven peptides for potential inclusion on the 503A Bulks List. This discussion extends beyond headlines about “popular unproven chemicals.” It is a regulatory and drug safety matter with direct implications for compounders and patients nationwide. We examine which peptides will be reviewed, the regulatory steps that follow the PCAC meeting, and what the outcome could mean for patient access and the broader future of personalized medicine.

503A, 503BAmy SummersJuly 13, 2026Peptides, Compounding, Compounding Bulk Drug Substances

Compounding Essentially a Copy FAQs

Some of the most prevalent questions compounding pharmacies and 503B outsourcers ask have to do with the do’s and don’ts of compounding essential copies of drugs. To help compounders sift through the confusion and interpretation, we discuss the most frequently asked questions about compounding an essential copy of an approved drug and provide real life examples.

FDA Removes Two Bulk Drug Substances Nominated for Use in 503B Outsourcing Facilities

This month, the FDA published final guidance for the list of bulk drug substances 503B facilities may use in compounding. The FDA decided to remove two substances from the previous version. This is a huge win for Big Pharma and a major loss for the compounding industry.

503A + 503B Compounding News

© 2019-2026 restore

Info

Action